CRISPR Therapeutics (Switzerland)

Recent papers from CRISPR Therapeutics (Switzerland)

1. Durability of CRISPR-Cas9 Gene Editing Targeting ANGPTL3 with CTX310New England Journal of Medicine · 2026
2. Claudin-1 targeting suppresses tumor growth, invasion, and metastasis in patient-derived cholangiocarcinoma modelsScience Translational Medicine · 2026
3. Fully Modified SpyCas9 Guide RNAs Enable Robust Genome Editing In Cells and In Vivo2026
4. Safety and efficacy of allogeneic CD19-directed CAR-T therapy CTX110 in relapsed/refractory B-cell non-Hodgkin lymphomaBlood Advances · 2026
5. Allogeneic CRISPR-Engineered CAR-T Cells Drive Potent Antitumor Activity in Solid Tumors2026
6. Abstract LB340: Mechanism-based trial matching reveals a 54% target alignment gap in ovarian cancer: Quantifying the precision-eligible ovarian cancer patientsCancer Research · 2026
7. Abstract 2235: Intercepting metastasis: 8-step CRISPR design via multi-modal foundation models.Cancer Research · 2026
8. Ethical and Regulatory Considerations for Developing Gene Therapies Involving Genome EditingHuman Gene Therapy · 2026
9. WCN26-6849 PREDICTING IGA NEPHROPATHY PROGRESSION: A HISTOPATHOLOGICAL APPROACH USING PARIETAL EPITHELIAL CELLS AND PODOCYTE MARKERS - PARCC IgAN ScoreKidney International Reports · 2026
10. Challenges and limitations of mobilization and stem cell collection for gene therapy of sickle cell diseaseBlood Advances · 2025
11. Engasertib versus Placebo for Bleeding in Hereditary Hemorrhagic TelangiectasiaNew England Journal of Medicine · 2025
12. Phase 1 Trial of CRISPR-Cas9 Gene Editing Targeting ANGPTL3New England Journal of Medicine · 2025
13. Deep learning‐enhanced 3D imaging unveils semaglutide impact on cardiac fibrosisBritish Journal of Pharmacology · 2025
14. Engineered microRNA scaffolds for potent gene silencing in vivoScientific Reports · 2025
15. Intent to Cure: The Need for a Rare Disease Platform in India and Across the Global SouthThe CRISPR Journal · 2025
16. PathCrisp: an innovative molecular diagnostic tool for early detection of NDM-resistant infectionsScientific Reports · 2025
17. Anti-CD7 allogeneic WU-CART-007 in patients with relapsed/refractory T-cell acute lymphoblastic leukemia/lymphoma: a phase 1/2 trial2024
18. A phase 1/2, open-label, multicenter, dose escalation and cohort expansion study of the safety and efficacy of anti-CD70 allogeneic CRISPR-Cas9–engineered T cells (CTX131) in adult patients with relapsed or refractory solid tumors.Journal of Clinical Oncology · 2024
19. Advancing Sewage Sample Surveillance with OmiCrisp: A CRISPR-Based Platform for Variant-Specific SARS-CoV-2 Detection2024
20. Harnessing autoimmunity with dominant self-peptide: Modulating the sustainability of tissue-preferential antigen-specific Tregs by governing the binding stability via peptide flanking residuesJournal of Autoimmunity · 2023